How Regeneron Pharmaceuticals (REGN) Makes Money: A Visual Guide
Regeneron Pharmaceuticals (REGN) generated $14.34B in revenue (TTM through Q4 2025), earning $4.50B in net profit (31.4% margin). Its largest revenue source is Collaboration Revenue (51.1% of revenue). Below is an interactive breakdown of how revenue flows through the income statement.
Regeneron Pharmaceuticals (REGN) Income Statement Flow
Frequently asked questions
How does Regeneron Pharmaceuticals (REGN) make money?
- Regeneron Pharmaceuticals (REGN) primarily makes money through Collaboration Revenue, which accounts for 51.1% of total revenue. For TTM through Q4 2025, Regeneron Pharmaceuticals generated $14.34B in total revenue with a net profit margin of 31.4%.
What is Regeneron Pharmaceuticals (REGN) gross profit margin?
- Regeneron Pharmaceuticals (REGN) reported a gross profit margin of 85.4% for TTM through Q4 2025, equivalent to $12.24B in gross profit. This means Regeneron Pharmaceuticals retains 85.4% of each revenue unit after direct costs of production.
What is Regeneron Pharmaceuticals (REGN) operating profit margin?
- Regeneron Pharmaceuticals (REGN) reported an operating profit margin of 24.9% for TTM through Q4 2025, equivalent to $3.58B in operating profit. This reflects profitability after operating expenses such as R&D, sales, and administration, but before taxes and non-operating items.
What is Regeneron Pharmaceuticals (REGN) net profit margin?
- Regeneron Pharmaceuticals (REGN) reported a net profit margin of 31.4% for TTM through Q4 2025, equivalent to $4.50B in net profit. This is the share of revenue that remains as profit after all expenses, taxes, and non-operating items.
How much does Regeneron Pharmaceuticals (REGN) invest in R&D?
- Regeneron Pharmaceuticals (REGN) invested $5.96B in research and development in TTM through Q4 2025 (41.5% of total revenue). R&D spending reflects investment in future products, services, and technologies.
How much does Regeneron Pharmaceuticals (REGN) spend on capital expenditures?
- Regeneron Pharmaceuticals (REGN) spent $898.40M on capital expenditures in TTM through Q4 2025 (6.3% of total revenue). Capital expenditures represent investments in physical assets such as property, equipment, and infrastructure.
What is Regeneron Pharmaceuticals (REGN) free cash flow?
- Regeneron Pharmaceuticals (REGN) generated $4.08B in free cash flow for TTM through Q4 2025 (28.4% of total revenue). Free cash flow is the cash remaining after capital expenditures and represents the company's ability to fund growth, pay dividends, or reduce debt.
What is Regeneron Pharmaceuticals (REGN) effective tax rate?
- Regeneron Pharmaceuticals (REGN) had an effective tax rate of 13.9% for TTM through Q4 2025. This is the actual percentage of pre-tax income paid as income taxes.
About this data
- What is a Sankey diagram?
- A Sankey diagram shows how money flows through a company from revenue to net profit. The width of each flow represents its proportion.
- How is the data calculated?
- We use the income statement from company filings. For TTM (Trailing Twelve Months), we sum the last four quarters. Revenue flows to cost of revenue and gross profit, then to operating expenses (R&D, S&M, G&A) and operating profit.
- When was this data last updated?
- Based on company filings through TTM through Q4 2025.